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Abstract
Background: Cryopreserved platelet products can be stored for years and are
mainly used in military settings. Following thawing, cryopreserved platelets
are activated, resulting in faster clot formation but reduced aggregation in
vitro, rendering their efficacy in bleeding unknown. Also, concerns remain on
the safety of these products. The aim was to investigate the efficacy and safety
of cryopreserved platelets in a rat model of traumatic hemorrhage.
Study Design and Methods: After 1 hour of shock, rats (n = 13/group) were
randomized to receive a balanced transfusion pack (1:1:1 red blood cell:plasma:
platelet) made from syngeneic rat blood, containing either liquid stored platelets
or cryopreserved platelets. Primary outcome was the transfusion volume
required to obtain a mean arterial pressure (MAP) of 60 mmHg. Secondary
Sources of support: Stichting Ziektekostenverzekering Krijgsmacht (SZVK) and the Dutch Ministry of Defense.
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outcomes were coagulation as assessed by thromboelastometry (ROTEM®) and
organ failure as assessed by biochemistry and histopathology.
Results: The transfusion volume to obtain a MAP of 60 mmHg was lower in
animals receiving cryopreserved platelets (5.4 [4.1-7.1] mL/kg) compared to
those receiving liquid stored platelets (7.5 [6.4-8.5] mL/kg, p < 0.05). ROTEM®
clotting times were shorter (45 [41-48] vs. 49 [45-53]sec, p < 0.05), while maxi-
mum clot firmness was slightly lower (68 [67-68] vs. 69 [69-71]mm, p < 0.01).
Organ failure was similar in both groups.
Conclusions: Use of cryopreserved platelets required less transfusion volume
to reach a targeted MAP compared to liquid stored platelets, while organ injury
was similar. These results provide a rationale for clinical trials with
cryopreserved platelets in (traumatic) bleeding.
1 | INTRODUCTION
Trauma-induced coagulopathy is characterized by platelet
dysfunction.1,2 Whereas platelet counts can be preserved
during traumatic bleeding, platelet dysfunction occurs in
approximately 45% of trauma patients.1-3 In accordance,
transfusion of high doses of platelets results in a reduction
in early death following trauma compared to lower doses
of platelets.4,5 Liquid stored platelet products however,
have a limited shelf-life (5-7 days at room temperature).
Cryopreservation of platelets increases the lifespan of these
products from days to years, rendering cryopreserved
platelets suitable for use in austere and military environ-
ments.6 Following thawing, cryopreserved stored platelets
are activated and show impaired aggregation and adhesion
in vitro.7 Also, recovery in vivo following autologous trans-
fusion of thawed cryopreserved platelets is reduced com-
pared to fresh autologous platelet products in healthy
volunteers.8 However, despite these observations, initiation
of clot formation occurs faster and fibrin formation is unaf-
fected.9 Cryopreserved platelet products have been used in
military and civilian settings, and in terms of clinical out-
come, appear to have a similar performance compared to
other platelet products.6,10-12 Despite these findings and
the fact that cryopreservation could potentially resolve
problems with availability or waste of platelet products,
widespread use of cryopreserved platelets is hampered,
which is probably due to a perceived loss of function of the
platelets.7,13-15 However, impaired aggregation in vitro and
a reduced recovery in vivo do not correlate with the hemo-
static potential of cryopreserved platelets.11 In contrast,
cryopreserved platelets induce a more rapid hemostatic
control compared to standard stored products in vitro, pre-
sumably as a result of activation, a high platelet-derived
extracellular vesicle content and an increased thrombin
generating capacity.16 In addition to questions relating to
the ability of cryopreserved platelet to control bleeding,
questions concerning their safety remain. The advantage
of the freeze-thawing-induced activation of the platelets
for controlling bleeding may also have the disadvantage of
an increased risk of thromboembolic events.17 Further-
more, cryopreserved platelets have been shown to have
immune-modulating effects in vitro and to augment a pro-
inflammatory response with ensuing organ injury, as
observed in mice.18
The aim of this study is to compare the hemostatic
capacity of cryopreserved with liquid stored platelets in a
rat model of traumatic hemorrhagic shock and to investi-
gate the impact on organ injury. We hypothesized that
resuscitation with cryopreserved platelets requires less
volume to restore hemostasis and shock when compared
to liquid stored platelets.
2 | MATERIALS AND METHODS
2.1 | Ethics, species and intervention
This study was approved by the Institutional Animal Care
and Use Committee of the Amsterdam University Medical
Centers, location Academic Medical Center. The proce-
dures were performed in accordance with the European
Parliament directive (2010/63/EU) and the national law the
Experiments on Animals Act (Wod, 2014). Animals were
group housed (2 to 4 rats per cage) with access to water and
food (2016 Teklad global 16% protein, Envigo, USA) ad
libitum at least 7 days before the experiment. The light-dark
cycle was from 7 AM until 7 PM. Experiments began at 8 AM,
traumatic shock was completed around 10 AM and ended at
4 PM. A total 26 male Sprague Dawley rats weighing 350-400
grams (Envigo, UK) were subjected to a model of multiple
trauma with uncontrolled liver bleeding.
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2.2 | Experimental model
2.2.1 | Blood component manufacturing
methods
Forty syngeneic donor rats were used for the preparation
of blood products as described before.19,20 In short, whole
blood was obtained through cardiac puncture and pre-
pared and stored according to national blood bank stan-
dards. Whole blood was mixed in a 9-to-1 ratio with
citrate-phosphate-dextrose solution, after which blood
was immediately centrifuged (10 min, 1892G, 20°C) to
separate the blood in three different components. Most
plasma was removed and stored at −80°C for 1 day. Two
buffy coats were removed and diluted with the rest of
plasma until a hematocrit of 20% was obtained. Thereaf-
ter, to remove remaining red blood cells and leukocytes,
the plasma diluted pooled buffy coat was centrifuged
(10 min, 300G, 22°C) and platelet-rich supernatant
plasma was obtained. Platelet-rich plasma was either
kept on a roller bank in a temperature-controlled stove at
22°C to be used in the next 2 days or was further
processed to cryopreserved platelets. The remaining
(buffy coat removed) red blood cells were diluted to a
hematocrit of 60% with additive solution (saline adeno-
sine glucose mannitol SAGM) and stored at 4°C to be
used the next day. One day after blood component pro-
duction and storage, the products were (thawed and)
used for transfusion.
The process to manufacture small volumes
cryopreserved platelets was developed by the Dutch mili-
tary blood bank, mimicking the procedure for human
cryopreserved platelets.21-24 Dimethylsulfoxide (DMSO)
27% in saline (BloodStor® 27 NaCl Biopreservation
Media; Biolife solutions Bothell, WA, USA) was added to
fresh rat platelet-rich plasma in four equal steps (30 sec
between steps) while gently stirring to a final DMSO con-
centration of 6%. Next, this product was centrifuged
(10 min, 1250G, 22°C, acceleration 9, brake 0, Eppendorf
4904R). Supernatant was removed (150 μL was left on the
pellet) and the pelleted platelets of the product were
suspended during 1 minute with slow pipetting move-
ments. To lower the freezing rate, which makes the freez-
ing process comparable to human products, the product-
tube was first wrapped in tissue paper in such a way that
the wrapped tube fits in a 50 mL falcon tube. Thereafter,
the package was placed upright in an −80°C freezer. The
platelets were kept at −80°C before use. On the day of
use, cryopreserved platelets were unwrapped and thawed
for 5 minutes in a 37°C water bath, after which platelets
were suspended with slow pipetting movements for
30 seconds while the tube was still in the water bath.
Warm (35-37°C) thawed plasma product was added
rapidly to the suspended platelet pellet while the tube
was mixed on a vortex in order to reconstitute the
cryopreserved platelet product to the same volume of
plasma as the liquid stored rat platelets. The thawed
suspended rat platelets were used within 15 minutes after
preparation.
When this process was piloted with small volume
cryopreserved human platelets, it resulted in >80% in vitro
recovery, which was comparable to recovery of standard
volume cryopreserved human platelet products (data not
shown). Also, the in vitro thromboelastography coagula-
tion characteristics of small volume cryopreserved human
platelets were comparable to that of normal volume
cryopreserved human platelet products (data not shown).
2.2.2 | Model of traumatic bleeding
Animals received induction anesthesia with ketamine
(Alfasan, The Netherlands), dexmedetomidine (Orion
Pharma, Finland) and atropine (Dechra, The Nether-
lands) and maintenance anesthesia with ketamine and
dexmedetomidine intravenously. A tracheostomy was
performed and rats were connected to a mechanical ven-
tilator (Babylog 8000, Draeger, Germany). Pressure-con-
trolled ventilation was applied with respiratory rate set at
60/min, a positive end expiratory pressure of 3.5 kPa and
inspiratory pressures of 10 kPa, yielding tidal volumes
between 7-8 mL/kg. Recruitment was performed every
hour by increasing inspiratory pressures (Pinsp) to 25 kPa
for 5 seconds. Respiratory rate was increased to 75/min
during traumatic hemorrhagic shock. In case of a high
PCO2 (>35 mmHg) with a low pH (<7.3), Pinsp was
increased by 2 kPa. Monitoring of arterial blood pressure
and blood sampling was done via an arterial catheter
placed in the right carotid artery. The right jugular vein
was cannulated and used for transfusion. Temperature
was monitored with a rectal thermometer and kept
between 36.5-37.0°C using a heat table and heat lamp.
Traumatic injury was inflicted by a fracture of the
right femur employing a guillotine. Following a median
laparotomy, crush injury of the small intestine was
inflicted by clamping the gut five times approximately
2 cm from the Treitz ligament with 0.2 cm in-between
the injuries. Isovolumic hemodilution was done with
Ringerʼs Lactate (Baxter, USA) according to the formula
(0.30(0.06 × weight + 0.770).25 The liver was punctured
at the left lateral lobe using a stance to penetrate a cir-
cumference of 0.5 cm of the liver, leading to uncontrolled
bleeding. The episode of uncontrolled bleeding lasted for
15 minutes with an open abdomen. If blood pressure did
not drop below a mean arterial pressure (MAP) of
40 mmHg, a maximum of 1.5 mL of blood (in addition to
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the isovolumic hemodilution) was drawn from the
carotid artery line (controlled hemorrhage). If MAP
dropped below 30 mmHg within the 15 minutes of
uncontrolled bleeding period, the liver was packed with
gauzes. After 15 minutes, the abdomen was closed to
maintain adequate body temperatures. Total hemorrhage
was the sum of controlled blood loss (baseline sample
+ maximum 1.5 mL during shock) and uncontrolled
blood loss (estimation of blood loss in the abdomen).
After a total shock duration of 1 hour (15 min uncon-
trolled bleeding +45 min of MAP<40 mmHg), rats were
randomized to receive resuscitation with a 1:1:1 volume
ratio of red blood cell:plasma:liquid stored platelets (liq-
uid stored) or 1:1:1 volume ratio of red blood cell:plasma:
cryopreserved platelets (cryopreserved). Transfusion was
set at a speed of 8.0 mL/hour. After reaching a MAP of
60 mmHg for 5 minutes, transfusion was stopped. Thirty
minutes before termination of the experiment (at
5.5 hours), a FITC-labeled 70 kDa dextran was adminis-
tered to assess endothelial barrier leakage. After
euthanization by bloodletting, the circulation was flushed
against gravitational force with 50 mL NaCl 0.9%. Both
vascular supply of the left lung and left kidney were tied-
off during this process to assess wet/dry ratios of these
organs. Wet weight was measured by measuring the
weight of the left lung/kidney, drying the organ for 1 week
at 60°C, and reevaluating the weight of the dried organ.
2.2.3 | Measurements during the
experiment
Blood samples were obtained just before trauma (T0),
after 1 hour of shock and just before initiation of transfu-
sion (T1), at 3 hours (T3), at 4 hours (T4) and after
6 hours at termination of the experiment and subsequent
euthanization of the animals (T6). Blood was assessed for
arterial blood gas and electrolytes at all time points and
rotational thromboelastometry (ROTEM® Delta, Werfen,
Spain) at four time points (T0, T1, T3, and T6). Thrombo-
cyte count (XN-9000, Sysmex, Japan), hemoglobin/
hematocrit (RAPIDPoint 500, Siemens Healtineers, Ger-
many), prothrombin time and Clauss fibrinogen level
(CS2500, Siemens Healthineers, Germany), aspartate trans-
aminase, alanine transaminases, creatinine (Cobas c702,
Roche, Switzerland) and urine protein (Cobas c502, Roche,
Switzerland) were measured at two time points (T0, T6).
2.2.4 | Rotational thromboelastometry
The EXTEM assay evaluates the extrinsic coagulation
pathway, using tissue factor and phospholipids to initiate
coagulation. Clotting time (CT) determines time to clot
initiation, the alpha angle assesses the rate of clot forma-
tion, maximum clot firmness (MCF) represents the
strength of the clot and the 30 minutes lysis index shows
the percentage of amplitude decrease 30 minutes after
maximum clot firmness, indicating clot lysis. The
FIBTEM assay uses EXTEM initiators of coagulation plus
a potent platelet inhibitor (cytocholasin D) to eliminate
platelet contribution to evaluate the contribution of
fibrinogen to clot formation. To assess the platelet com-
ponent of clot formation, the FIBTEM MCF value is sub-
tracted from the EXTEM MCF value.
2.2.5 | Enzyme-linked immunosorbent
assays (ELISA)
Levels of circulating syndecan-1, a component of the
endothelial glycocalyx, and high mobility group protein
B1 (HGMB-1),26 damage marker released from predomi-
nantly platelets, were measured with ELISAs according
to manufacturerʼs guidelines (eLabscience, USA).
2.2.6 | Organ assessments
The hematoxylin and eosin slides of the lung, liver, spleen,
small intestine, and kidney were scored by a pathologist,
who was blinded to treatment allocation. This scoring sys-
tem has been used before.19,20 The lung, for example, was
scored based on lung edema, interstitial inflammatory cell
infiltration, endothelialitis, and hemorrhage. The scale of
each category consisted of a score of 0 (=absent) to 3
(=severe). For the full scoring list see Table S1, available as
supporting information in the online version of this paper.
2.2.7 | Immunostaining FITC-dextran
leakage
Deparaffinized blanco organ slides of the lung and kidney
were colored using a rabbit - anti-FITC/anti-rabbit horse
radish peroxidase and NovaRed coloring method. The stop-
ping times were kept constant for all slides. Five different
images of each organ, blinded for the treatment allocation
to the assessor, were obtained with microscope (10x zoom)
and camera (BX51 with UC90, Olympus, Japan). Pictures
were inverted using Image J. Five random inverted pictures
were used to set a threshold indicating presence of FITC-
70 kDa dextran leakage. Median percentage of area inten-
sity was used as measure for endothelial leakage.
2.3 | Sample size calculation
Based on previous experiments,19 given a treatment effect
of 0.6 mL/kg and a standard deviation of 0.47 mL/kg, 11
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rats per group have a power of 80% to detect a statistical
significant difference in transfusion volume needed to
reach a MAP of 60 mmHg. Because we previously experi-
enced a mortality of 20% in our model, we added two
additional rats per group, yielding 13 per experimental
group.
2.4 | Statistical analysis
Data were analyzed using SPSS (IBM, version 25.0),
graphs were made using GraphPad Prism (version 8.0.2).
All parameters were first assessed for distribution and
checked for normality using a Kolmogorov-Smirnov test
and by visual inspection of histograms. Data were pres-
ented based on their distribution as median with inter-
quartile range, mean with standard deviation or
percentage. Parameters were tested for differences using
the Mann-Whitney U test, Student T test, or Chi-Squared
test. Paired (T0 vs. T6) nonparametric differences were
tested within groups with a Friedman ANOVA. A p value
of less than 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Trauma, shock, and transfusion
needs
Traumatized animals were in severe shock in both
groups, indicated by high base deficits, increased lactate
levels and low blood pressures without significant differ-
ences between group (Table 1, Fig. 1). Controlled blood
loss (baseline sample + additional bloodletting) plus esti-
mated uncontrolled blood (estimated volume of blood
loss in the abdomen) loss during the shock period were
not different between cryopreserved and liquid stored
platelet treated rats (total blood loss of 9.6 [8.8-10.1] vs.
9.7 [9.0-10.3] mL, p = 0.84). All animals survived the 6-
hour time point.
Quality assessments of the different blood products
are described in the Table S2, available as supporting
information in the online version of this paper. The rat
cryopreserved platelet product yielded a median in vitro
freeze-thaw recovery of 87% [69-100]. The volume of
transfusion needed to restore circulation to the pre-
determined MAP of 60 mmHg was significantly lower in
the cryopreserved platelet transfused rats compared to
the liquid stored platelet transfused rats (5.4 [4.1-7.1]
mL/kg vs. 7.5 [6.4-8.5] mL/kg, p = 0.02). The degree of
shock as assessed by lactate levels and base deficits was
similar in both groups. These variables remained similar
between groups over the course of the experiment.
3.2 | Coagulation
Our trauma and shock model resulted in decreased plate-
let counts, prolonged prothrombin time and decreased
fibrinogen levels, without differences between groups.
Thrombocyte counts were equal also at the end of the
experiment (Table 2). Both groups remained coagulopathic
TABLE 1 Parameters at baseline, after traumatic shock and after resuscitation strategy
Liquid stored platelets Cryopreserved platelets
Parameter
Before
injury (T0)
After injury
and shock (T1)
After
transfusion
(T3)
Before
injury (T0)
After injury and
shock (T1)
After
transfusion
(T3)
Weight (gram) 359 (344-373) ND ND 346 (339-366) ND ND
pH 7.39 (7.37-7.45) 7.41 (7.37-7.43) 7.41 (7.37-7.42) 7.43 (7.39-7.47) 7.39 (7.32-7.45) 7.40 (7.36-7.42)
pCO2 (mmHg) 34.9 (31.0-41.4) 24.9 (23.8-27.4) 28.8 (26.2-30.1) 36.5 (33.9-38.9) 23.8 (21.2-32.1) 28.3 (23.4-32.3)
BE (mEq/L) −0.7 (−2.3-0.1) −8.0 (−8.6-−6.8) −6.0 (−8.3-−5.6) 0.0 (−2.0-1.6) −8.0 (−11.0 - −6.0) −7.3 (−8.2 - −6.1)
Lactate (mmol/L) 0.7 (0.6-0.8) 3.7 (3.1-4.9) 2.3 (2.0-2.9) 0.7 (0.6-0.7) 3.8 (2.8-7.4) 2.1 (1.6-3.4)
Na+ (mmol/L) 139 (138-140) 130 (128-134) 137 (135-140) 139 (138-141) 131 (129-132) 138 (136-139)
K+ (mmol/L) 4.1 (3.9-4.6) 5.9 (5.7-6.8) 5.8 (5.4-6.1) 4.1 (3.9-4.3) 6.3 (6.0-6.7) 5.7 (5.3-6.0)
Ca2+ (mmol/L) 1.0 (1.0-1.1) 1.0 (0.9-1.1) 1.1 (1.0-1.2) 1.1 (1.1-1.1) 1.1 (1.0-1.1) 1.1 (1.0-1.1)
Cl− (mmol/L) 107 (105-108) 104 (100-108) 107 (106-112) 107 (105-108) 104 (101-107) 109 (108-111)
Glucose (mmol/L) 18.4 (17.1-20.1) 31.3 (29.9-36.6) 22.5 (19.8-24.7) 17.6 (17.3-18.8) 34.7 (30.4-35.5) 20.1 (17.9-21.3)
Note: Data are presented as median (IQR).
Abbreviations: BE, base excess; ND, not determined.
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after trauma and resuscitation, as shown by approximately
1.3 times prolonged prothrombin times compared to base-
line, without differences between the cryopreserved (13.9
[12.2-14.4] sec) and the liquid stored platelet treated group
(14.2 [12.7-15.8] sec, p = 0.36). Also, fibrinogen levels
remained low in both groups 6 hours post injury, without
differences in the cryopreserved platelet group (1.3 [1.1-
1.6] g/L) compared to the liquid stored platelet group (1.3
[1.0-1.4] g/L, p = 0.34). The ROTEM® assays were mea-
sured at multiple time points (Fig. 2). Trauma, blood loss,
and saline dilution reduced FIBTEM clot strength but
did not significantly affect EXTEM clot strength or
clotting times within 1 hour after trauma. Two hours
following transfusion, EXTEM clotting time was signifi-
cantly shorter in the cryopreserved platelet treated rats
(45 [41-48] sec) compared to the liquid stored platelet
group (49 [45-53] sec, p < 0.05), while maximum clot
firmness was slightly but significantly decreased (68 [67-
68] mm vs. 69 [69-71] mm, p < 0.01). The platelet con-
tribution to clot formation was similar between the
cryopreserved group compared to the liquid stored
platelet group (57 [55-57] mm vs. 59 mm [54-60],
p = 0.06). There was no lysis present during this experi-
ment in both groups.
3.3 | Organ injury
Trauma resulted in acute lung, acute kidney, and acute
liver injury (Table 2, Fig. 3). Lung injury did not reveal
differences between cryopreserved and liquid stored
platelet treated rats, depicted by similar lung wet/dry
ratios (5.5 [5.2-5.7] vs. 5.2 [4.7-5.6], p = 0.22) and similar
lung histology scores (Fig. 3). Kidney injury was not dif-
ferent, with similar creatinine levels and kidney wet/dry
ratios in the cryopreserved platelet (4.3 [3.9-4.7]) vs. liq-
uid stored platelets (4.3 [3.7-4.6], p = 0.88). In addition,
groups did not differ in leakage of FITC-dextran from the
circulation into the lung and kidney (Table 2). Syndecan-
1, a marker for glycocalyx degradation, was elevated after
trauma, but was not different between groups. Thereby,
cryopreserved platelets compared to liquid stored plate-
lets had no impact on endothelial permeability. Also,
liver injury did not differ between groups, as determined
by similar ALT (alanine transaminase) levels. Assessing
organ histology scores revealed no differences between
groups (Fig. 3). Thrombus formation was only observed
on the site where injury was directly inflicted, without
differences between groups. No thrombi were observed in
organs without direct traumatic injury. Individual scores
FIGURE 1 Shock and resuscitation needs. Data are median with interquartile ranges. (A) Mean arterial pressure. Between T0 and T1:
1 hour shock phase; between T1 and T2: transfusion phase. Three hours,3 4 hours,4 and 6 hours6 after trauma additional blood samples were
taken. (B) Transfusion until MAP 60 mmHg. (C) Lactate. (D) Base excess. Rats were treated with either a balanced 1:1:1 red blood cell:
plasma:platelet with liquid-stored platelets or a balanced transfusion ratio with cryopreserved platelets. Dotted vertical line represents when
resuscitation was initiated. *p < 0.05 between groups
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of the different organs are shown in Fig. S1, available as
supporting information in the online version of this
paper. HMGB-1 is a damage molecule that is released
from platelets. The level of HMGB-1 was markedly ele-
vated after traumatic shock, however there were no sig-
nificant differences between the liquid stored platelet
group and the cryopreserved platelet group.
4 | DISCUSSION
In this model of uncontrolled traumatic bleeding, a bal-
anced transfusion strategy containing cryopreserved
platelets required 28% less blood product volume to reach
a targeted MAP when compared to a strategy using liq-
uid-stored platelets. Reduced transfusion needs were
associated with a faster initiation of clot formation as
assessed by ROTEM®, but lower clot amplitude. Use of
cryopreserved platelets was comparable to treatment with
liquid stored platelets in terms of organ injury.
In our model, the lower volume of transfusion needed
to restore MAP to a predefined target in the
cryopreserved platelet treated rats, may be attributed to
the faster clotting times that were observed with
ROTEM®. These data are in line with previous in vitro
data, that showed that cryopreserved platelets reduced
clotting times compared to liquid stored platelets.27-29
The reason why cryopreserved platelets compared to liq-
uid stored platelets reduce ROTEM clotting times might
be due to increased procoagulant microparticle content
and increased thrombin generation.16,30 We found that
clot firmness was slightly reduced in the cryopreserved
platelet group, although this effect was smaller than
found in previous in vitro studies.7,9,16 Reduction in clot
firmness most likely was not due to lower fibrinogen
activity, as fibrinogen levels as well as ROTEM® FIBTEM
did not differ between groups. Thereby, the reduction in
clot strength in the cryopreserved group may be due to
reduced platelet function. In line with this, results of the
MCF EXTEM minus FIBTEM were also lower in the
cryopreserved platelet group when compared to the liq-
uid platelet group. The differences in clot firmness were
however very small (median difference of 1 mm) and it is
not clear whether this reflects clinical relevance. Our data
suggest that a balanced transfusion with cryopreserved
platelets is possibly better for achieving hemostasis com-
pared to liquid stored platelets, even when clot firmness
is somewhat reduced. In line with this, cryopreserved
platelets formed similar amounts of fibrin in in vitro flow
models compared to liquid stored platelets,21 which also
TABLE 2 Coagulation, endothelial leakage, and biochemical assessment of organ injury
Parameter
Liquid stored platelets Cryopreserved platelets
Before injury (T0) After 6 hours (T6) Before injury (T0) After 6 hours (T6)
Hemoglobin (mmol/L) 9.2 (8.9-9.4) 6.3 (5.7-6.5) 9.0 (8.6-9.6) 6.4 (5.8-6.6)
Hematocrit (%) 44 (42-44) 30 (27-31) 43 (41-46) 30 (27-31)
Coagulation and HMGB-1
Thrombocytes (*109/L) 975 (917-998) 511 (399-654)** 904 (832-1003) 448 (376-509)**
Fibrinogen (g/L) 2.3 (2.1-2.4) 1.3 (1.0-1.4)** 2.2 (2.1-2.4) 1.3 (1.1-1.6)**
PT (sec) 10.8 (10.6-10.9) 14.2 (12.7-15.8)** 10.7 (10.5-10.9) 13.9 (12.2-14.4)**
HMGB-1 (ng/mL) 1.4 (1.3-1.8) 25.5 (13.5-33.1)** 1.5 (1.3-1.6) 21.5 (10.2-26.1)**
Endothelial leakage
Syndecan-1 (ng/mL) 61.0 (42.7-106.6) 136.6 (108.7-173.1)** 54.9 (46.5-64.4) 105.1 (86.4-150.8)**
Area FITC leakage-lung (%) NA 13.2 (7.0-20.0) NA 14.3 (9.5-18.0)
Area FITC leakage-kidney (%) NA 20.0 (13.4-28.6) NA 25.6 (20.7-29.8)
Biochemical assessment of organ injury
ALT (U/L) 49.5 (44.3-53.5) 1315.0 (872.0-1822.0)** 52.0 (48.5-57.5) 1093.0 (685.0-1635.0)**
AST (U/L) 58.0 (54.0-65.0) 2733.0 (1436.5-3598.5)** 61.0 (57.0-63.0) 1656 (1123.0-3276.0)**
Creatinine (μmol/L) 24.0 (24.0-26.5) 142.0 (104.5-156.5)** 24.0 (23.0-25.5) 145.0 (128.0-155.0)**
Urine protein (g/L) 0.6 (0.4-1.0) 1.7 (1.3-1.9) * 0.9 (0.7-1.0) 1.7 (1.6-2.2)*
Note: Data are presented as median (IQR). *p < 0.05 within group (T0-T6), **p < 0.01 within group (T0-T6). No significant between group
differences were detected.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; FITC, fluorescein isothiocyanate; HMGB-1, high mobility group
protein B1; NA, not applicable; PT, prothrombin time.
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suggests that decreased in vitro platelet functions of
cryopreserved platelets such as clot strength, aggregation,
and adhesion may not be clinically relevant to reduce
bleeding in vivo.
Clinical data comparing the efficacy of cryopreserved
platelets to liquid stored platelets in patients are sparse.
In an older cardiac surgery trial, cryopreserved platelet
transfusion resulted in less blood loss and less blood
product use compared to liquid stored platelets.11 This
result was however not reproduced in a more recent pilot
trial in cardiac surgery patients, in which no difference in
blood loss was shown between groups.12 Notably,
patients treated with liquid stored platelet were twice
more likely to have a postoperative bleeding compared to
patients treated with cryopreserved platelets.12 In obser-
vational studies in trauma patients, the efficacy of
cryopreserved platelets was comparable to historical con-
trols treated with liquid stored platelets.10 Our data add
to the rationale of designing a follow-up trial investigat-
ing efficacy.
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represented as median with
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In terms of safety, we found no significant differences in
endothelial leakage, edema, or organ injury between
groups. Previously, in a mouse model of controlled bleeding,
use of cryopreserved platelets was associated with high ALT
levels, hepatic macrophage infiltration, and hepatic
myeloperoxidase activity compared to liquid stored platelet
treated mice.31 An explanation for these different results
may be the use of a different transfusion model. In the pre-
sent study, cryopreserved platelets in plasma were adminis-
tered in addition to red blood cells, whereas only platelets
in plasma were transfused in the mouse model.31 Further-
more, HMGB-1 levels were not different between groups in
this study. Damaged cells and platelets release HMGB-1.
HMGB-1 acts as an alarmin and is positively correlated with
neutrophil activation, thrombosis and organ failure in
trauma.17,32-34 We found no evidence that cryopreserved
platelets resulted in HMGB-1-mediated inflammation.
The current model has some limitations. This study
was designed employing a pressure-fixed transfusion tar-
get as primary outcome. The group of cryopreserved
platelets required less transfusion volume compared to
liquid stored platelet group. As transfusion is associated
with organ injury, we cannot exclude that transfusion of
equal volumes would have resulted in higher organ
injury scores in the cryopreserved group. However, in
clinical practice, a pressure-fixed target is commonly used
as resuscitation goal to minimize transfusion. The resusci-
tation target of 60 mmHg was chosen based on a previous
study in which a target of 60 mmHg compared to other
targets did not result in increased mortality, did not
increase interleukin levels, reduced blood loss and reduced
amount of fluid therapy.35 Furthermore, rats differ in their
coagulation system compared to humans, including higher
ranges of platelet counts, hampering translation to
humans.36 However, similar to humans, rats also encoun-
ter a platelet dysfunction due to traumatic shock.37
In conclusion, transfusion of cryopreserved platelets in
a rat trauma transfusion model results in improved
clotting time and reduced blood transfusion requirements.
In terms of organ injury, cryopreserved platelets appear to
be as safe as liquid stored platelets. The results provide a
rationale for clinical studies investigating the efficacy and
safety of cryopreserved platelets in traumatic bleeding.
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FIGURE 3 Organ histology scores. Data are presented as boxplot with total range. Cumulative scores of the (A) lung, (B) kidney, (C)
liver, and (D) small intestine are shown. For individual scores and total spleen score: see Fig. S1, available as supporting information in the
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